Evidence map›Paper›PMID 42470818›Full record

ArticleBiomaterials advances2026

Systematic engineering of Layer-by-Layer anti-miR coated wound dressings with tunable release kinetics.

Adam G Berger, Chau Vo, Justin A Kaskow, Shruti Rawal, Eva Cai, Elad Deiss-Yehiely, Namita Nabar, Tamara G Dacoba, Michael Marand, Joon Ho Park and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Adam G BergerHarvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA; Institute for Soldier Nanotechnologies, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Chau VoHarvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA; Institute for Soldier Nanotechnologies, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Justin A KaskowKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA; Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Shruti RawalCardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Eva CaiHarvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Elad Deiss-YehielyKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA; Department of Materials Science and Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Namita NabarKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA; Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA; Broad Institute of Harvard and MIT, Cambridge, MA, 02139, USA.
Tamara G DacobaKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Michael MarandKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Joon Ho ParkKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA; Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Gil CovarrubiasKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Charles DeLorenzoInstitute for Soldier Nanotechnologies, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA; Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Mark W FeinbergCardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: mfeinberg@bwh.harvard.edu.
Paula T HammondKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA; Institute for Soldier Nanotechnologies, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA; Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA; Broad Institute of Harvard and MIT, Cambridge, MA, 02139, USA. Electronic address: hammond@mit.edu.

Funding

Medical Scientist Training ProgramT32GM144273 · NIGMS · HARVARD MEDICAL SCHOOL · PI David Shumway Jones, Jacqueline A. Lees · 2022 to 2026
$14.7M
MiR-181b, endothelial cells, and vascular inflammationR01HL115141 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI FEINBERG, MARK W · 2012 to 2024
$6.8M
Discovery and therapeutic targeting non-coding RNAs in T1D- or T2D-associated atherosclerosisU01DK142281 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI MARK W FEINBERG · 2024 to 2026
$3.1M
LncRNA MERRICAL, macrophage chemotaxis, and diabetes-associated atherosclerosisR01HL171239 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI FEINBERG, MARK W · 2024 to 2025
$1.3M
miR-130b, angiogenesis, and diabetic critical limb ischemiaR01HL167905 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI FEINBERG, MARK W · 2024 to 2025
$1.3M
Non-coding RNAs and chronic limb threatening ischemiaR35HL183402 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI MARK W FEINBERG · 2026 to 2026
$1.2M
Controlled release of RNA-targeting therapy to promote healing of diabetic ulcersF30DK130564 · NIDDK · HARVARD MEDICAL SCHOOL · PI BERGER, ADAM G · 2021 to 2025
$257k
NHLBI NIH HHS R01 HL115141NHLBI NIH HHS R01 HL167905NHLBI NIH HHS R01 HL171239NHLBI NIH HHS R35 HL183402NIDDK NIH HHS F30 DK130564NIDDK NIH HHS U01 DK142281NIGMS NIH HHS T32 GM144273
6 · The paper itself

Abstract

The Layer-by-Layer (LbL) technique enables conformal coating of commercial wound dressings with oligonucleotide therapeutics and polymeric excipients to achieve controlled delivery to non-healing wounds. We previously demonstrated a proof-of-concept LbL dressing containing miRNA inhibitors (anti-miRs); however, release occurred on a single time scale. Because wound healing is dynamic, temporally tuning anti-miR delivery to the wound may alter therapeutic effects. Here, we provide an approach to modulate oligonucleotide release kinetics from coated wound dressings, exploring the design space of excipients, formulation parameters, and oligonucleotide structure. Incorporation of Laponite nanoclay prolonged release, while poly(acrylic acid) accelerated release kinetics. Hydrolyzable poly(β-amino esters) with varying hydrolysis rates were also used to further tune release kinetics. A fast-release formulation demonstrated 40% release over 4 h, while a slow-release formulation took 24 h to release the same amount. We evaluated these dressings in an excisional chronic wound model in diabetic (db/db) mice using anti-miR-92a (92ai), selected for its ability to enhance angiogenic signaling and promote wound closure. Dressings coated with 92ai accelerated healing compared to non-targeting scramble anti-miR (Scr) controls, with closure rates accelerated at times corresponding to release kinetics. Although ultimate wound closure was similar across release conditions, analyses of gene expression, cellular composition, histology, and immunofluorescence suggested distinct underlying mechanisms. Differences were particularly evident in macrophage phenotype and angiogenesis, suggesting that release timing influences biological pathways active during repair. Overall, these findings demonstrate that LbL dressings can be engineered for temporally controlled oligonucleotide delivery and that release kinetics may shape mechanisms driving wound closure.

Indexed as

BandagesMicroRNAsWound HealingAnimalsDelayed-Action PreparationsKineticsMiceDelayed-Action PreparationsMicroRNAsAngiogenesisAnti-miRControlled releaseLayer-by-LayerNanoclayOligonucleotideRelease kineticssiRNAThin filmsWound healing

Identifiers

PMID42470818
PMCPMC13690477

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.